REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Merdury Biopharmaceutical Corporation (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Merdury Biopharmaceutical Corporation Profile Updated: February 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English & Chinese Download a sample report

Mercury Biopharmaceutical Corporation is engaged in in rapid-acting and specialty drug development. The company’s main products rapid-acting and specialty drugs. The company was established in 2019 and is headquartered in New Taipei City, Taiwan.

Headquarters
15F.,No. 653-1, Bannan Rd., Zhonghe Dist
New Taipei City; New Taipei City;

Contact Details: Purchase the Merdury Biopharmaceutical Corporation report to view the information.

Website: http://merdury.com

Basic Information
Total Employees:
Purchase the Merdury Biopharmaceutical Corporation report to view the information.
Outstanding Shares:
Purchase the Merdury Biopharmaceutical Corporation report to view the information.
Financial Auditors:
Purchase the Merdury Biopharmaceutical Corporation report to view the information.
Incorporation Date:
July 16, 2019
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
6.41%
Purchase this report to view the information.
5.58%
Purchase this report to view the information.
5.29%
Purchase this report to view the information.
0.13%
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Merdury Biopharmaceutical Corporation report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
-109.18%▼
EBITDA
-102.49%▼
Net Profit (Loss) for the Period
-96.38%▼
Total assets
133.63%▲
Total equity
174.13%▲
Return on Equity (ROE)
1.8%▲
Debt to Equity Ratio
-17.57%▼
Quick Ratio
38.35%▲
Cash Ratio
-18.59%▼

Similar companies

Lotus Pharmaceutical Co., Ltd.
 
Great Tree Pharmacy Co.,Ltd.
Bora Pharmaceuticals Co., Ltd.
 
China Chemical & Pharmaceutical Co., Ltd
Pharmally International Holding Co., Ltd
 
Taiwan Biotech Co., Ltd.
Andros Pharmaceuticals Co., Ltd.
 
Formosa Pharmaceuticals, Inc.
Gongwin Biopharm Holdings Co., Ltd.
 
Senhwa Biosciences, Inc.
Alar Pharmaceuticals Inc.
 

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo